Investor Presentaiton slide image

Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 6 Sales growth of 4% measured in local currencies mainly driven by Victoza®, OzempicⓇ and SaxendaⓇ - Sales as reported – first nine months of 2018 Other Growth disorders biopharmaceuticals (1%) (14%) % Haemophilia 6% (8%) 9% Obesity 42% 3% 81% Growth break down Local currencies - Growth first nine months of 2018 Share of growth (7%) 3% (2%) 1% (2%) Long-acting insulin¹ Premix insulin² Fast-acting insulin³ (7%) Human insulin 1% 2% Diabetes care (2%) Total insulin (1%) (9%) GLP-14 18% 84% Other diabetes care5 2% 1% Total diabetes care 4% 76% Obesity (SaxendaⓇ) 53% 28% Diabetes care and obesity total 5% 104% Haemophilia (3%) (6%) Growth disorders (NorditropinⓇ) 5% 6% Other biopharmaceuticals? (10%) (4%) Biopharmaceuticals (1%) 4% (4%) 100% Sales of DKK 82.1 billion (2%) changing diabetes Total 1 Comprises Tresiba®, XultophyⓇ and LevemirⓇ: 2 Comprises RyzodegⓇ and NovoMix® 3 Comprises FiaspⓇ and NovoRapidⓇ; 4 Comprises VictozaⓇ and Ozempic® 5 Primarily NovoNorm® and needles; 6 Comprises NovoSeven®, NovoEight® NovoThirteenⓇ and Refixia®; 7 Primarily Vagifem® and Activelle®
View entire presentation